Bulent OZPOLAT

Dr. Bulent Ozpolat  is serving as a Professor at the Department of Experimental Therapeutics at MD Anderson Cancer Center, The University of Texas-Houston,Houston, TX, USA.  After getting his M.D. degree from The University of Dokuz Eylul University Medical School, Izmir, Turkey, Dr. Ozpolat was accepted to the Graduate program at The M. D. Anderson Cancer Center—The University of Texas-and received his Ph.D. degree in Immunology in 1999.  Dr. Ozpolat completed his post doctoral training   at MD Anderson Cancer Center at Houston Medical Center and specialized in Cancer biology, Genetics, Gene therapy, Nanotechnology  and development of highly targeted targeted Therapeutics.

Dr. Ozpolat’s  laboratory at MD Anderson currently  focuses on 1)  identification of molecular targets in highly aggressive cancers such as breast, pancreatic ovarian 2) Development of highly targeted therapeutics (including gene silencing therapies and small molecule inhibitors.

 Dr. Ozpolat is a member of Center for Targeted Therapy (CTT) and Non-Coding RNA center at MD Anderson Cancer Center and Graduate School of Biomedical sciences at The University of Texas. Dr  received many research awards in recognition of research excellence.  Dr. Ozpolat has 3 patents and  published more than 90 publications (60 papers, 9 book chapter sand 14 review articles) in peer-reviewed high impact journals  such as New England J of Medicine, Cell, Nature, Oncotarget, Cell Death and disease, Cancer Research, Clinical Cancer Research, Apoptosis, Molecular Cancer Theraputics, Autophagy, J of Internal Medicine etc ) and contributed to textbooks. Dr. currently serve as an editor , associate editor and editorial board members of several journals ( ie, Translational Genetics and Genomics, Nanomedicine & Nanotechnology, Advances in Modern Oncology Research) and international External Advisory board of several Turkish Universities and work as a reviewer for US Congressionally Directed Medical research Department of Defense-Breast cancer and Immunology study sections, Italian health Ministry-Cancer, and Polish academy of Science and British Cancer Foundation.